General Information
Mouse: Swiss Webster x CB57BL/DAB
Expression of the mutant A53T human alpha-synuclein under the control of the rat tyrosine hydroxylase (TH) promoter.
Endogenous mouse alpha synuclein: Yes.
Corresponding human genotype: Autosomal dominant mutation in PD patients (PARK1); early onset disease
Transgene insertion: not specified
References: Matusoka 2001; Manning-Bog 2003
Transgene expression
- 12 months: Transgene expression is observed in the brainstem, midbrain neurons, olfactory bulb and retinal anacrine cells. High protein levels are detected in nigrostriatal dopamine neurons.
Neurodegeneration
- 12 months: No loss of TH-positive neurons is observed. Reduced sensitivity to paraquat toxicity is detected.
Dopamine Homeostasis
- No changes observed
Inclusions
- 12 months: no inclusions are detected
Motor Behaviours
- Not reported
Response to L-DOPA treatment
- Not reported
Non motor Behaviours
- Not reported
Electrophysiology
- Not reported
Neuroinflammation
- Not reported